← Back to Search

Other

ANX007 for Age-Related Macular Degeneration (ARCHER Trial)

Phase 2
Waitlist Available
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 18
Awards & highlights

ARCHER Trial Summary

This trial is testing a new drug to see if it can stop or slow the growth of vision loss from GA due to AMD. It will last about 19 months.

Who is the study for?
This trial is for people with a specific eye condition called geographic atrophy (GA) due to age-related macular degeneration. Participants must have GA lesions of certain sizes, clear vision within specified limits, and no other major eye diseases or treatments that could interfere with the study. Women must not be pregnant or breastfeeding and should use effective contraception.Check my eligibility
What is being tested?
The trial tests if ANX007 injections into the eye can slow down lesion growth in patients with GA secondary to AMD compared to sham injections. The study spans roughly 19 months and aims to inform further development of ANX007 for treating this eye condition.See study design
What are the potential side effects?
While specific side effects are not listed here, intravitreal injections like ANX007 may cause eye discomfort, redness, bleeding inside the eye (hemorrhage), increased pressure in the eye, cataracts, or infection.

ARCHER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
GA lesion growth rate
Secondary outcome measures
Best corrected visual acuity (BCVA)
Low-luminance BCVA (LL-BCVA)
Low-luminance visual acuity deficit (LL-VD)
+1 more

ARCHER Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: ANX007 Group 2Experimental Treatment1 Intervention
ANX007 administered every other month
Group II: ANX007 Group 1Experimental Treatment1 Intervention
ANX007 administered every month
Group III: Sham Group 4Placebo Group1 Intervention
Sham injection administered every other month
Group IV: Sham Group 3Placebo Group1 Intervention
Sham injection administered every month
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX007
2018
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
12 Previous Clinical Trials
528 Total Patients Enrolled
Clinical TrialsStudy DirectorAnnexon, Inc.
2,202 Previous Clinical Trials
889,766 Total Patients Enrolled

Media Library

ANX007 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04656561 — Phase 2
~64 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top